Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycle LONDON, Dec. 4, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of...
Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1
AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end...
The St. Regis Macao Presents the House of Celebration this Festive Season
Timeless rituals and curated indulgences inspire a season of sophisticated wonder MACAO, Nov. 25, 2025 /PRNewswire/ -- The St. Regis Macao is delighted to unveil its enchanting programme of festive celebrations, transforming the hotel into the...
Phrozen Presents ARCO: Fast, Full-Color FDM 3D Printing for Creative Minds
TAIPEI, Nov. 10, 2025 /PRNewswire/ -- Phrozen, renowned for its leadership in resin 3D printing, expands its ecosystem with a refreshed look at ARCO, the company's first FDM 3D printer. Building on its reputation for high-precision printing, Phrozen...
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) Data suggest the potential to...
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved...
HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025...
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. The non-inferiority...
AEWIN Presents Innovative Two-Phase Direct Liquid Cooling (2P DLC) Solution at SC25
TAIPEI, Nov. 5, 2025 /PRNewswire/ -- AEWIN Technologies Co., Ltd (doing business as AEWIN), a leading provider of advanced network appliances and edge computing solutions, is excited to present innovative Two-Phase Direct Liquid Cooling (2P DLC)...
HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD - L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. TAIPEI, SHANGHAI,...